ROCKET PHARMACEUTICALS, INC. Income Statement
RCKT|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
ROCKET PHARMACEUTICALS, INC. reported $0 in revenue and $259M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $102.0M | $58.8M | $41.8M | $28.9M | $18.2M | $17.9M | $17.9M | $1.6M |
| R&D Expense | $171.2M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M | $53.3M | $6.0M |
| Operating Income | -$273.2M | -$224.3M | -$167.2M | -$134.3M | -$76.2M | -$71.2M | -$71.2M | -$7.6M |
| Interest Expense | $1.9M | $1.9M | $3.0M | $7.0M | $6.0M | $6.0M | $6.0M | $0 |
| Income Tax | $0 | - | $0 | - | - | - | - | - |
| Net Income | -$258.7M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M | -$74.5M | -$7.6M |
| EPS (Basic) | -$2.73 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | - | - | - |
| EPS (Diluted) | -$2.73 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | -$1.89 | -$1.89 | -$1.11 |
| Shares Outstanding | 106.5M | 90.3M | 79.1M | 64.5M | 61.0M | 54.8M | 45.1M | 6.8M |